Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Decibel Therapeutics announces study on noise-related inner ear damage

By Brian Buntz | September 30, 2021

Decibel TherapeuticsDecibel Therapeutics (NSDQ:DBTX) has a working hypothesis that molecular characterization of the cell biology of the inner ear could pave the way for treatments for hearing and balance disorders. 

The Boston-based biotech company has announced that a recent study published in Cell Reports supports that hypothesis. 

“We were thrilled to leverage our data and expertise in inner ear biology to help fuel this analysis, which may help enable identification of therapeutics that counter the observed trends in gene expression that occur following noise exposure,” said Joe Burns, vice president, discovery at Decibel Therapeutics, in a statement. 

The company partnered with the University of Maryland School of Medicine and the Karolinska Institute on the research.

Decibel Therapeutics had its IPO on February 12. Its shares have since fallen from $18.03 apiece to $7.71 today.

Other hearing-loss-focused pharmaceutical forms have also see wide declines.

For instance, Otonomy (NSDQ:OTIC) has had its shares fall from $39.36 on March 13, 2015 to $1.92 today.

Similarly, Lexington, Massachusetts–based Frequency Therapeutics has also seen its stock plunge from $55.01 on February 19 to $7.06 today. 

On March 23, Frequency Therapeutics (NSDQ:FREQ) announced that interim results indicated that its lead pipeline candidate FX-322 was ineffective at improving mild to moderately severe sensorineural hearing loss in a Phase 2a study compared to placebo. Earlier that month, the company said the drug seemed to lead to hearing improvements in adults with age-related hearing loss. 

Frequency Therapeutics recently announced that several subjects receiving FX-322 in a small open-label study showed statistically significant hearing improvement eight to 12 months after initial dosing. 


Filed Under: ENT drugs
Tagged With: Cell Reports, Decibel Therapeutics, Frequency Therapeutics, FX-322, Otonomy
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Pfizer
Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates
Decibel Therapeutics
Decibel Therapeutics touts progress with lead gene therapy product candidate DB-OTO
Otonomy
Investigational tinnitus drug shows promise in Phase 1/2 study
Bell's palsy
Man experiences facial palsy twice after receiving both COVID-19 vaccine doses

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50